デフォルト表紙
市場調査レポート
商品コード
1000988

大麻医薬品市場調査レポート:ブランド別(Epidiolex、Sativex)-2026年までの予測-COVID-19の累積的影響

Cannabis Pharmaceuticals Market Research Report by Brand, by Product Type, by Distribution Channel, by Application, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19

出版日: | 発行: 360iResearch LLP | ページ情報: 英文 190 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=114.08円
大麻医薬品市場調査レポート:ブランド別(Epidiolex、Sativex)-2026年までの予測-COVID-19の累積的影響
出版日: 2021年10月08日
発行: 360iResearch LLP
ページ情報: 英文 190 Pages
納期: 即日から翌営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の大麻医薬品の市場規模は、2020年の8億7,257万米ドルから、2025年末までに19億7,267万米ドルに成長すると予測されています。

COVID-19は、未曾有の世界的な公衆衛生上の緊急事態であり、あらゆる業界に影響を及ぼしてきました。この長期的影響は、予測期間中に業界の成長に影響を与えると予測されています。私たちが進めている調査では、根底にあるCOVID-19の問題と今後の道筋を確実に扱うために、調査範囲を広げています。当レポートは、消費者の行動と需要の変化、購入パターン、サプライチェーンの再ルーティング、現在の市場動向、および政府の重要な介入などを考慮しながら、COVID-19について洞察を提供しています。アップデートされた調査では、COVID-19が市場に及ぼす影響を考慮し、洞察、分析、予測などを提供しています。

当レポートでは、大麻医薬品市場について調査し、市場の概要とともに、ブランド別、地域別の動向、COVID-19の累積的影響、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 序文

  • 調査の目的
  • 市場セグメンテーションと範囲
  • 調査対象年
  • 通貨と価格
  • 言語
  • 制限事項
  • 利害関係者

第2章 調査手法

  • 調査プロセス
    • 定義:調査目的
    • 決定:調査デザイン
    • 準備:調査機器
    • 収集:データソース
    • 分析:データの解釈
    • 策定:データ検証
    • 公開:調査レポート
    • 繰り返し:レポートの更新
  • 調査の実行
    • 開始:調査プロセス
    • 計画:調査計画作成
    • 実行:調査実施
    • 検証:発見と分析
    • 出版物:調査報告
  • 調査成果

第3章 エグゼクティブサマリー

  • イントロダクション
  • 市場の見通し
  • ブランド別見通し
  • 地域別見通し
  • 競合他社別見通し

第4章 市場概要

  • イントロダクション
  • COVID-19の累積的影響

第5章 市場の洞察

  • 市場力学
    • 促進要因
    • 抑制要因
    • 市場機会
    • 課題
  • ポーターズファイブフォース分析
    • 新規参入業者の脅威
    • 代替品の脅威
    • 顧客の交渉力
    • 供給企業の交渉力
    • 業界の競争

第6章 世界の大麻医薬品市場、ブランド別

  • Epidiolex
  • Sativex

第7章 南北アメリカの大麻医薬品市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第8章 アジア太平洋の大麻医薬品市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • 韓国
  • タイ

第9章 欧州、中東・アフリカの大麻医薬品市場

  • フランス
  • ドイツ
  • イタリア
  • オランダ
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • アラブ首長国連邦
  • 英国

第10章 競合情勢

  • FPNVポジショニングマトリックス
    • 象限
    • 事業戦略
    • 製品の満足度
  • 市場ランキング分析
  • 市場シェア分析
  • 競合他社のSWOT分析
  • 競合シナリオ
    • 合併と買収
    • 合意、コラボレーション、およびパートナーシップ
    • 新製品の発売と強化
    • 投資と資金調達
    • 賞、表彰、拡大

第11章 企業のユーザビリティプロファイル

  • AbbVie Inc.
  • Amyris, Inc.
  • Aphria, Inc.
  • Aurora Cannabis, Inc.
  • Botanix Pharmaceuticals
  • Breath of Life Pharma, Ltd.
  • Cannabis Science, Inc.
  • Canopy Growth Corporation
  • Cara Therapeutics
  • CB Therapeutics Inc.
  • Corbus Pharmaceuticals Holdings, Inc.
  • Cronos Group Inc.
  • GW Pharmaceuticals, PLC
  • Insys Therapeutics, Inc.
  • Medical Marijuana Inc.
  • Medicure Pharmaceuticals
  • MedReleaf Corp.
  • MGC Pharmaceuticals Limited
  • Pascal Biosciences Inc.
  • PharmaCyte Biotech, Inc.
  • Serina Therapeutics, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Tilray, Inc.
  • Valeant Pharmaceuticals
  • Zynerba Pharmaceuticals, Inc.

第12章 付録

  • ディスカッションガイド
  • ライセンスと価格
図表

LIST OF FIGURES

  • FIGURE 1. GLOBAL CANNABIS PHARMACEUTICALS MARKET: RESEARCH PROCESS
  • FIGURE 2. GLOBAL CANNABIS PHARMACEUTICALS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 3. GLOBAL CANNABIS PHARMACEUTICALS MARKET: MARKET DYNAMICS
  • FIGURE 4. GLOBAL CANNABIS PHARMACEUTICALS MARKET SIZE, BY BRAND, 2020 VS 2026 (%)
  • FIGURE 5. GLOBAL CANNABIS PHARMACEUTICALS MARKET SIZE, BY BRAND, 2020 VS 2026 (USD MILLION)
  • FIGURE 6. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL CANNABIS PHARMACEUTICALS MARKET SIZE, BY BRAND, 2026
  • FIGURE 7. GLOBAL CANNABIS PHARMACEUTICALS MARKET SIZE, BY EPIDIOLEX, 2018-2026 (USD MILLION)
  • FIGURE 8. GLOBAL CANNABIS PHARMACEUTICALS MARKET SIZE, BY EPIDIOLEX, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 9. GLOBAL CANNABIS PHARMACEUTICALS MARKET SIZE, BY SATIVEX, 2018-2026 (USD MILLION)
  • FIGURE 10. GLOBAL CANNABIS PHARMACEUTICALS MARKET SIZE, BY SATIVEX, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 11. GLOBAL CANNABIS PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2020 VS 2026 (%)
  • FIGURE 12. GLOBAL CANNABIS PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2020 VS 2026 (USD MILLION)
  • FIGURE 13. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL CANNABIS PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2026
  • FIGURE 14. GLOBAL CANNABIS PHARMACEUTICALS MARKET SIZE, BY OINTMENTS & CREAMS, 2018-2026 (USD MILLION)
  • FIGURE 15. GLOBAL CANNABIS PHARMACEUTICALS MARKET SIZE, BY OINTMENTS & CREAMS, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 16. GLOBAL CANNABIS PHARMACEUTICALS MARKET SIZE, BY SOLIDS AND DISSOLVABLE POWDER & OIL, 2018-2026 (USD MILLION)
  • FIGURE 17. GLOBAL CANNABIS PHARMACEUTICALS MARKET SIZE, BY SOLIDS AND DISSOLVABLE POWDER & OIL, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 18. GLOBAL CANNABIS PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2020 VS 2026 (%)
  • FIGURE 19. GLOBAL CANNABIS PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2020 VS 2026 (USD MILLION)
  • FIGURE 20. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL CANNABIS PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2026
  • FIGURE 21. GLOBAL CANNABIS PHARMACEUTICALS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2026 (USD MILLION)
  • FIGURE 22. GLOBAL CANNABIS PHARMACEUTICALS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 23. GLOBAL CANNABIS PHARMACEUTICALS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2026 (USD MILLION)
  • FIGURE 24. GLOBAL CANNABIS PHARMACEUTICALS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 25. GLOBAL CANNABIS PHARMACEUTICALS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2026 (USD MILLION)
  • FIGURE 26. GLOBAL CANNABIS PHARMACEUTICALS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 27. GLOBAL CANNABIS PHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2020 VS 2026 (%)
  • FIGURE 28. GLOBAL CANNABIS PHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2020 VS 2026 (USD MILLION)
  • FIGURE 29. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL CANNABIS PHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2026
  • FIGURE 30. GLOBAL CANNABIS PHARMACEUTICALS MARKET SIZE, BY ARTHRITIS, 2018-2026 (USD MILLION)
  • FIGURE 31. GLOBAL CANNABIS PHARMACEUTICALS MARKET SIZE, BY ARTHRITIS, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 32. GLOBAL CANNABIS PHARMACEUTICALS MARKET SIZE, BY CANCER, 2018-2026 (USD MILLION)
  • FIGURE 33. GLOBAL CANNABIS PHARMACEUTICALS MARKET SIZE, BY CANCER, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 34. GLOBAL CANNABIS PHARMACEUTICALS MARKET SIZE, BY EPILEPSY, 2018-2026 (USD MILLION)
  • FIGURE 35. GLOBAL CANNABIS PHARMACEUTICALS MARKET SIZE, BY EPILEPSY, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 36. GLOBAL CANNABIS PHARMACEUTICALS MARKET SIZE, BY MIGRAINE, 2018-2026 (USD MILLION)
  • FIGURE 37. GLOBAL CANNABIS PHARMACEUTICALS MARKET SIZE, BY MIGRAINE, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 38. AMERICAS CANNABIS PHARMACEUTICALS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 39. ARGENTINA CANNABIS PHARMACEUTICALS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 40. BRAZIL CANNABIS PHARMACEUTICALS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 41. CANADA CANNABIS PHARMACEUTICALS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 42. MEXICO CANNABIS PHARMACEUTICALS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 43. UNITED STATES CANNABIS PHARMACEUTICALS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 44. ASIA-PACIFIC CANNABIS PHARMACEUTICALS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 45. AUSTRALIA CANNABIS PHARMACEUTICALS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 46. CHINA CANNABIS PHARMACEUTICALS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 47. INDIA CANNABIS PHARMACEUTICALS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 48. INDONESIA CANNABIS PHARMACEUTICALS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 49. JAPAN CANNABIS PHARMACEUTICALS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 50. MALAYSIA CANNABIS PHARMACEUTICALS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 51. PHILIPPINES CANNABIS PHARMACEUTICALS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 52. SINGAPORE CANNABIS PHARMACEUTICALS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 53. SOUTH KOREA CANNABIS PHARMACEUTICALS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 54. TAIWAN CANNABIS PHARMACEUTICALS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 55. THAILAND CANNABIS PHARMACEUTICALS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 56. EUROPE, MIDDLE EAST & AFRICA CANNABIS PHARMACEUTICALS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 57. FRANCE CANNABIS PHARMACEUTICALS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 58. GERMANY CANNABIS PHARMACEUTICALS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 59. ITALY CANNABIS PHARMACEUTICALS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 60. NETHERLANDS CANNABIS PHARMACEUTICALS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 61. QATAR CANNABIS PHARMACEUTICALS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 62. RUSSIA CANNABIS PHARMACEUTICALS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 63. SAUDI ARABIA CANNABIS PHARMACEUTICALS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 64. SOUTH AFRICA CANNABIS PHARMACEUTICALS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 65. SPAIN CANNABIS PHARMACEUTICALS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 66. UNITED ARAB EMIRATES CANNABIS PHARMACEUTICALS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 67. UNITED KINGDOM CANNABIS PHARMACEUTICALS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 68. GLOBAL CANNABIS PHARMACEUTICALS MARKET: FPNV POSITIONING MATRIX
  • FIGURE 69. GLOBAL CANNABIS PHARMACEUTICALS MARKET: SHARE, BY KEY PLAYER, 2020
  • FIGURE 70. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL CANNABIS PHARMACEUTICALS MARKET, BY TYPE

LIST OF TABLES

  • TABLE 1. GLOBAL CANNABIS PHARMACEUTICALS MARKET: MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
  • TABLE 3. GLOBAL CANNABIS PHARMACEUTICALS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 4. GLOBAL CANNABIS PHARMACEUTICALS MARKET SIZE, BY BRAND, 2018-2026 (USD MILLION)
  • TABLE 5. GLOBAL CANNABIS PHARMACEUTICALS MARKET SIZE, BY EPIDIOLEX, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 6. GLOBAL CANNABIS PHARMACEUTICALS MARKET SIZE, BY SATIVEX, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 7. GLOBAL CANNABIS PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2026 (USD MILLION)
  • TABLE 8. GLOBAL CANNABIS PHARMACEUTICALS MARKET SIZE, BY OINTMENTS & CREAMS, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 9. GLOBAL CANNABIS PHARMACEUTICALS MARKET SIZE, BY SOLIDS AND DISSOLVABLE POWDER & OIL, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 10. GLOBAL CANNABIS PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD MILLION)
  • TABLE 11. GLOBAL CANNABIS PHARMACEUTICALS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 12. GLOBAL CANNABIS PHARMACEUTICALS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 13. GLOBAL CANNABIS PHARMACEUTICALS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 14. GLOBAL CANNABIS PHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2026 (USD MILLION)
  • TABLE 15. GLOBAL CANNABIS PHARMACEUTICALS MARKET SIZE, BY ARTHRITIS, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 16. GLOBAL CANNABIS PHARMACEUTICALS MARKET SIZE, BY CANCER, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 17. GLOBAL CANNABIS PHARMACEUTICALS MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 18. GLOBAL CANNABIS PHARMACEUTICALS MARKET SIZE, BY MIGRAINE, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 19. AMERICAS CANNABIS PHARMACEUTICALS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 20. ARGENTINA CANNABIS PHARMACEUTICALS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 21. BRAZIL CANNABIS PHARMACEUTICALS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 22. CANADA CANNABIS PHARMACEUTICALS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 23. MEXICO CANNABIS PHARMACEUTICALS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 24. UNITED STATES CANNABIS PHARMACEUTICALS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 25. ASIA-PACIFIC CANNABIS PHARMACEUTICALS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 26. AUSTRALIA CANNABIS PHARMACEUTICALS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 27. CHINA CANNABIS PHARMACEUTICALS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 28. INDIA CANNABIS PHARMACEUTICALS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 29. INDONESIA CANNABIS PHARMACEUTICALS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 30. JAPAN CANNABIS PHARMACEUTICALS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 31. MALAYSIA CANNABIS PHARMACEUTICALS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 32. PHILIPPINES CANNABIS PHARMACEUTICALS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 33. SINGAPORE CANNABIS PHARMACEUTICALS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 34. SOUTH KOREA CANNABIS PHARMACEUTICALS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 35. TAIWAN CANNABIS PHARMACEUTICALS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 36. THAILAND CANNABIS PHARMACEUTICALS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 37. EUROPE, MIDDLE EAST & AFRICA CANNABIS PHARMACEUTICALS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 38. FRANCE CANNABIS PHARMACEUTICALS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 39. GERMANY CANNABIS PHARMACEUTICALS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 40. ITALY CANNABIS PHARMACEUTICALS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 41. NETHERLANDS CANNABIS PHARMACEUTICALS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 42. QATAR CANNABIS PHARMACEUTICALS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 43. RUSSIA CANNABIS PHARMACEUTICALS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 44. SAUDI ARABIA CANNABIS PHARMACEUTICALS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 45. SOUTH AFRICA CANNABIS PHARMACEUTICALS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 46. SPAIN CANNABIS PHARMACEUTICALS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 47. UNITED ARAB EMIRATES CANNABIS PHARMACEUTICALS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 48. UNITED KINGDOM CANNABIS PHARMACEUTICALS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 49. GLOBAL CANNABIS PHARMACEUTICALS MARKET: SCORES
  • TABLE 50. GLOBAL CANNABIS PHARMACEUTICALS MARKET: BUSINESS STRATEGY
  • TABLE 51. GLOBAL CANNABIS PHARMACEUTICALS MARKET: PRODUCT SATISFACTION
  • TABLE 52. GLOBAL CANNABIS PHARMACEUTICALS MARKET: RANKING
  • TABLE 53. GLOBAL CANNABIS PHARMACEUTICALS MARKET: SHARE, BY KEY PLAYER, 2020
  • TABLE 54. GLOBAL CANNABIS PHARMACEUTICALS MARKET: MERGER & ACQUISITION
  • TABLE 55. GLOBAL CANNABIS PHARMACEUTICALS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
  • TABLE 56. GLOBAL CANNABIS PHARMACEUTICALS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
  • TABLE 57. GLOBAL CANNABIS PHARMACEUTICALS MARKET: INVESTMENT & FUNDING
  • TABLE 58. GLOBAL CANNABIS PHARMACEUTICALS MARKET: AWARD, RECOGNITION, & EXPANSION
  • TABLE 59. GLOBAL CANNABIS PHARMACEUTICALS MARKET: LICENSE & PRICING
目次
Product Code: MRR-221461476B57

The Global Cannabis Pharmaceuticals Market size was estimated at USD 872.57 million in 2020 and expected to reach USD 1,031.56 million in 2021, at a CAGR 18.55% to reach USD 2,423.25 million by 2026.

Market Statistics:

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage:

This research report categorizes the Cannabis Pharmaceuticals to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Brand, the market was studied across Epidiolex and Sativex.

Based on Product Type, the market was studied across Ointments & Creams and Solids and Dissolvable Powder & Oil.

Based on Distribution Channel, the market was studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.

Based on Application, the market was studied across Arthritis, Cancer, Epilepsy, and Migraine.

Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Cannabis Pharmaceuticals Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:

The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor's strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Cannabis Pharmaceuticals Market, including AbbVie Inc., Amyris, Inc., Aphria, Inc., Aurora Cannabis, Inc., Botanix Pharmaceuticals, Breath of Life Pharma, Ltd., Cannabis Science, Inc., Canopy Growth Corporation, Cara Therapeutics, CB Therapeutics Inc., Corbus Pharmaceuticals Holdings, Inc., Cronos Group Inc., GW Pharmaceuticals, PLC, Insys Therapeutics, Inc., Medical Marijuana Inc., Medicure Pharmaceuticals, MedReleaf Corp., MGC Pharmaceuticals Limited, Pascal Biosciences Inc., PharmaCyte Biotech, Inc., Serina Therapeutics, Inc., Teva Pharmaceutical Industries Ltd., Tilray, Inc., Valeant Pharmaceuticals, and Zynerba Pharmaceuticals, Inc..

The report provides insights on the following pointers:

  • 1. Market Penetration: Provides comprehensive information on the market offered by the key players
  • 2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
  • 3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
  • 4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
  • 5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

  • 1. What is the market size and forecast of the Global Cannabis Pharmaceuticals Market?
  • 2. What are the inhibiting factors and impact of COVID-19 shaping the Global Cannabis Pharmaceuticals Market during the forecast period?
  • 3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Cannabis Pharmaceuticals Market?
  • 4. What is the competitive strategic window for opportunities in the Global Cannabis Pharmaceuticals Market?
  • 5. What are the technology trends and regulatory frameworks in the Global Cannabis Pharmaceuticals Market?
  • 6. What is the market share of the leading vendors in the Global Cannabis Pharmaceuticals Market?
  • 7. What modes and strategic moves are considered suitable for entering the Global Cannabis Pharmaceuticals Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Define: Research Objective
  • 2.3. Determine: Research Design
  • 2.4. Prepare: Research Instrument
  • 2.5. Collect: Data Source
  • 2.6. Analyze: Data Interpretation
  • 2.7. Formulate: Data Verification
  • 2.8. Publish: Research Report
  • 2.9. Repeat: Report Update

3. Executive Summary

  • 3.1. Introduction

4. Market Overview

  • 4.1. Introduction
  • 4.2. Cumulative Impact of COVID-19

5. Market Dynamics

  • 5.1. Introduction
  • 5.2. Drivers
    • 5.2.1. Increase in the legalization of medicinal cannabis in economies
    • 5.2.2. Growing awareness about the medical benefits of cannabidiol and its remedial properties
    • 5.2.3. Growing usage of cannabis-based pharmaceuticals for various indications such as inflammation, chronic pain, sleep disorders, and others
  • 5.3. Restraints
    • 5.3.1. High price associated with the medical cannabis
  • 5.4. Opportunities
    • 5.4.1. Rise in investments by pharma companies in CBD and developments for cannabinoid regulation
    • 5.4.2. Innovation and launching new products
  • 5.5. Challenges
    • 5.5.1. Availability of various alternatives in the market

6. Cannabis Pharmaceuticals Market, by Brand

  • 6.1. Introduction
  • 6.2. Epidiolex
  • 6.3. Sativex

7. Cannabis Pharmaceuticals Market, by Product Type

  • 7.1. Introduction
  • 7.2. Ointments & Creams
  • 7.3. Solids and Dissolvable Powder & Oil

8. Cannabis Pharmaceuticals Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Hospital Pharmacies
  • 8.3. Online Pharmacies
  • 8.4. Retail Pharmacies

9. Cannabis Pharmaceuticals Market, by Application

  • 9.1. Introduction
  • 9.2. Arthritis
  • 9.3. Cancer
  • 9.4. Epilepsy
  • 9.5. Migraine

10. Americas Cannabis Pharmaceuticals Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Cannabis Pharmaceuticals Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand

12. Europe, Middle East & Africa Cannabis Pharmaceuticals Market

  • 12.1. Introduction
  • 12.2. France
  • 12.3. Germany
  • 12.4. Italy
  • 12.5. Netherlands
  • 12.6. Qatar
  • 12.7. Russia
  • 12.8. Saudi Arabia
  • 12.9. South Africa
  • 12.10. Spain
  • 12.11. United Arab Emirates
  • 12.12. United Kingdom

13. Competitive Landscape

  • 13.1. FPNV Positioning Matrix
    • 13.1.1. Quadrants
    • 13.1.2. Business Strategy
    • 13.1.3. Product Satisfaction
  • 13.2. Market Ranking Analysis
  • 13.3. Market Share Analysis, By Key Player
  • 13.4. Competitive Scenario
    • 13.4.1. Merger & Acquisition
    • 13.4.2. Agreement, Collaboration, & Partnership
    • 13.4.3. New Product Launch & Enhancement
    • 13.4.4. Investment & Funding
    • 13.4.5. Award, Recognition, & Expansion

14. Company Usability Profiles

  • 14.1. AbbVie Inc.
  • 14.2. Amyris, Inc.
  • 14.3. Aphria, Inc.
  • 14.4. Aurora Cannabis, Inc.
  • 14.5. Botanix Pharmaceuticals
  • 14.6. Breath of Life Pharma, Ltd.
  • 14.7. Cannabis Science, Inc.
  • 14.8. Canopy Growth Corporation
  • 14.9. Cara Therapeutics
  • 14.10. CB Therapeutics Inc.
  • 14.11. Corbus Pharmaceuticals Holdings, Inc.
  • 14.12. Cronos Group Inc.
  • 14.13. GW Pharmaceuticals, PLC
  • 14.14. Insys Therapeutics, Inc.
  • 14.15. Medical Marijuana Inc.
  • 14.16. Medicure Pharmaceuticals
  • 14.17. MedReleaf Corp.
  • 14.18. MGC Pharmaceuticals Limited
  • 14.19. Pascal Biosciences Inc.
  • 14.20. PharmaCyte Biotech, Inc.
  • 14.21. Serina Therapeutics, Inc.
  • 14.22. Teva Pharmaceutical Industries Ltd.
  • 14.23. Tilray, Inc.
  • 14.24. Valeant Pharmaceuticals
  • 14.25. Zynerba Pharmaceuticals, Inc.

15. Appendix

  • 15.1. Discussion Guide
  • 15.2. License & Pricing